The diagnostic value of narrow-band imaging for early and invasive lung cancer: a meta-analysis by Zhu, Juanjuan et al.
The diagnostic value of narrow-band imaging for early
and invasive lung cancer: a meta-analysis
Juanjuan Zhu,I,III Wei Li,I,III,* Jihong Zhou,V Yuqing Chen,I,III Chenling Zhao,I,III Ting Zhang,IV Wenjia Peng,II
Xiaojing WangI,III
IDepartment of Respiratory Disease, the First Affiliated Hospital of Bengbu Medical College, Bengbu 233004, China. IIDepartment of Epidemiology and
Health Statistics, Bengbu Medical College, Bengbu 233030, China. III Provincial Key Laboratory of Respiratory Disease in Anhui, Bengbu 233004, China
IVDepartment of Respiratory Disease, No.2 People’s Hospital of Fuyang City, Fuyang 236015, China. VDepartment of Biochemistry and Molecular Biology,
Bengbu Medical College, Bengbu 233004, China.
This study aimed to compare the ability of narrow-band imaging to detect early and invasive lung cancer with
that of conventional pathological analysis and white-light bronchoscopy. We searched the PubMed, EMBASE,
Sinomed, and China National Knowledge Infrastructure databases for relevant studies. Meta-disc software was
used to perform data analysis, meta-regression analysis, sensitivity analysis, and heterogeneity testing, and
STATA software was used to determine if publication bias was present, as well as to calculate the relative risks
for the sensitivity and specificity of narrow-band imaging vs those of white-light bronchoscopy for the detec-
tion of early and invasive lung cancer. A random-effects model was used to assess the diagnostic efficacy of
the above modalities in cases in which a high degree of between-study heterogeneity was noted with respect to
their diagnostic efficacies. The database search identified six studies including 578 patients. The pooled
sensitivity and specificity of narrow-band imaging were 86% (95% confidence interval: 83–88%) and 81% (95%
confidence interval: 77–84%), respectively, and the pooled sensitivity and specificity of white-light broncho-
scopy were 70% (95% confidence interval: 66–74%) and 66% (95% confidence interval: 62–70%), respectively.
The pooled relative risks for the sensitivity and specificity of narrow-band imaging vs the sensitivity and
specificity of white-light bronchoscopy for the detection of early and invasive lung cancer were 1.33 (95%
confidence interval: 1.07–1.67) and 1.09 (95% confidence interval: 0.84–1.42), respectively, and sensitivity anal-
ysis showed that narrow-band imaging exhibited good diagnostic efficacy with respect to detecting early and
invasive lung cancer and that the results of the study were stable. Narrow-band imaging was superior to white
light bronchoscopy with respect to detecting early and invasive lung cancer; however, the specificities of the
two modalities did not differ significantly.
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’ INTRODUCTION
Trend analyses of high-quality data from 22 registries,
including several population-based registries currently avail-
able in the National Central Cancer Registry of China, were
conducted in 2000–2011 and published in 2016. These anal-
yses suggested that an estimated 4,292,000 new cancer cases
and 2,814,000 cancer deaths would occur in China in 2015,
and they identified lung cancer as the most common incident
cancer and the leading cause of cancer-related death in the
country. Lung cancer is considered an important health threat
both in China and in other countries around the world and
has imposed significant medical and economic burdens on
society (1,2).
Surgery offers a relatively good possibility of a cure in
patients with early-stage lung cancer, and the 5-year sur-
vival rate for patients with stage Ia disease is 73%. However,
the 5-year survival rates range from 9% to 46% in patients
with more advanced disease (stages II–IV) (3). Currently,
only 16% of lung cancer are diagnosed when the disease is
localized, and even fewer lung cancer are diagnosed at stage
0, resulting in an overall 5-year survival rate of only 15%.
Therefore, early diagnosis and treatment are important, as
these factors are associated with an improved 5-year survival
rate and a better prognosis in patients with lung cancer (4).
Endoscopic examination remains the most direct and
effective method for detecting lung cancer. Narrow-band
imaging (NBI) is a new endoscopic technique designed to
detect pathologically altered mucosal and submucosal
microvascular patterns that uses the following two narrowDOI: 10.6061/clinics/2017(07)09
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light bandwidths: blue light (390–445 nm), which is absorbed
by superficial capillaries; and green light (530–550 nm), which
is absorbed by blood vessels inside capillary membranes.
These narrow bandwidths reduce light scattering (i.e., the
deeper the light penetrates into the mucosa, the stronger the
scattering) and enable enhanced blood vessel visualization.
This approach consequently improves contrast on the mucosal
surface, reduces examination times, and eliminates unneces-
sary biopsies (5).
Following the successful introduction of NBI in the field of
gastroenterology and the confirmation of its diagnostic value
for gastrointestinal malignancies, clinicians incorporated this
modality into interventional pulmonology. NBI has since
been used to diagnose lung diseases, especially early and
invasive lung cancer. Several studies have compared the ability
of NBI to detect early and invasive lung cancer (defined as
moderate and severe dysplasia or carcinoma in situ [CIS]) and
invasive lung cancer with that of pathological analysis (6-14).
The simplicity, reproducibility, and straightforward nature
of NBI evaluations of the tracheo-bronchial tree ensure that
NBI videobronchoscopy will play a significant role in lung
cancer detection and staging in the future. However, previous
publications have shown that the sensitivity and specificity of
NBI for these lesions vary widely (0.53–1.00 and 0.43–0.90,
respectively). However, most of these studies confirmed that
NBI was superior to white-light bronchoscopy (WLB) with
respect to detecting both early and invasive lung cancer
(7-10,13,14). Therefore, the present study aimed to conduct a
meta-analysis to evaluate the diagnostic efficacies of NBI and
WLB and to compare the ability of NBI to diagnose early and
invasive lung cancer with that of WLB.
’ MATERIALS AND METHODS
Search strategy
We searched the PubMed, EMBASE, Sinomed, and China
National Knowledge Infrastructure databases for relevant
studies published up to September 14, 2015. We focused on
English- and Chinese-language publications reporting the
diagnostic efficacy of NBI for early and invasive lung cancer.
The following search terms were used to ensure the list of
studies retrieved via the search was comprehensive: (‘‘Narrow
Band Imaging’’ OR ‘‘Narrowband Imaging’’ OR ‘‘Band Imaging,
Narrow’’ OR ‘‘Band Imagings, Narrow’’ OR ‘‘Imaging, Narrow
Band’’ OR ‘‘Imagings, Narrow Band’’ OR ‘‘Narrow Band
Imagings’’ OR ‘‘Imaging, Narrowband’’ OR ‘‘Imagings,
Narrowband’’ OR ‘‘Narrowband Imagings’’ OR ‘‘NBI’’ OR
‘‘Narrow-band Imaging’’) AND (‘‘Lungs’’ OR ‘‘Lung’’ OR
‘‘Pulmonary’’) AND (‘‘Humans’’ OR ‘‘Human’’).
First, all the records from the database search were imported
into Endnote to eliminate duplicate studies. Then, two eval-
uators (WL and JJZ) independently read the titles and abstracts
of the articles identified through the above searches to exclude
studies that did not meet the analysis inclusion criteria. Any
disagreements were resolved through discussion. Finally, the
full texts of the remaining studies were carefully reviewed so
that informed final decisions regarding their inclusion in the
study could be made. The reference lists of the included records
were also screened for relevant articles (Figure 1).
Literature inclusion and exclusion criteria
The following studies were included in the analysis:
(a) studies published in English or Chinese; (b) studies using
NBI to diagnose early and invasive lung cancer; (c) studies
using histopathological analysis as the reference standard
(i.e., the gold standard); (d) studies reporting sufficient data
for the construction of 2 2 contingency tables for the true
positive (TP), false positive (FP), false negative (FN), and true
negative (TN) rates of early or invasive lung cancer, as well
as studies reporting ‘‘per-lesion’’ or ‘‘per-patient’’ statistics;
and (e) studies including patients who underwent clinical or
radiological examinations because they were suspected of
having or known to have a lung malignancy or were at high
risk for lung cancer. When the same data sets or subsets were
presented in more than one article, only the article that
provided the greatest detail, was published most recently, or
had the highest level of quality was chosen. When abstracts
and studies did not report sufficient data, we did not attempt
to contact their authors to request additional information.
The following studies were excluded from the analysis: (1)
studies reporting data pertaining to histologically uncon-
firmed lesions; (2) studies reporting incomplete data; (3)
studies with overlapping data; and (4) letters, editorials,
expert opinions, reviews without original data, conference
abstracts, meta-analyses, case reports, studies with fewer
than 10 cases, and articles for which only the abstract could
be obtained.
Qualitative assessment
Study quality was evaluated using the Quality Assessment
of Diagnostic Accuracy Studies (QUADAS) tool (15), a vali-
dated tool that assesses diagnostic accuracy studies using
14 domains pertaining to the design and presentation of
study data. The possible responses to each question are
‘‘yes’’, ‘‘no’’, or ‘‘unclear’’ and are scored as 1, -1, and 0,
respectively. The assessment was performed by two inde-
pendent authors (WL and JJZ), and disagreements were
resolved by discussion.
Data extraction
Data pertaining to the numbers of TP, FP, FN, and TN
diagnoses were extracted, and histological pathological
findings served as the gold standard with which the above
modalities were compared. We constructed 2 2 tables con-
taining the number of cases of early or invasive lung cancer.
These data were extracted on both a ‘‘per-patient’’ and a
‘‘per-lesion’’ basis when possible. We also extracted data
regarding the first author’s name, year of publication, nation
of research origin, mean patient age, ratio of men to women,
number of lesions, number of patients, pathological results,
number of endoscopists and endoscopes, type of NBI system,
study design, and other relevant items (Table 1).
Data synthesis and analysis
Meta-disc (version 1.4) software was used to test the
threshold effect among the included studies by calculating
the Spearman correlation coefficient, to combine the indices
used to describe the diagnostic efficacy of NBI, and to con-
duct heterogeneity tests. Study heterogeneity was assessed
using the w2 test and I2 statistic. I2 values of 25%, 50%, and
75% were indicative of low, moderate, and high hetero-
geneity, respectively. If the I2 value exceeded 50%, or the
likelihood ratio w2 test yielded a p-valueo0.05, the data were
considered to exhibit significant statistical heterogeneity.
Therefore, we pooled the data pertaining to the sensitivity
and specificity of the above diagnostic tests using a random-
effects model to generate a more conservative estimate.
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The area under the summary receiver operating character-
istic curve (AUC) was used to analyse the lung cancer diag-
nostic efficacy of NBI. If significant heterogeneity was noted,
meta-regression was used to identify the sources. Subgroup
analysis was conducted to examine the diagnostic value of
various statistical indices, and sensitivity analysis was used
to assess the stability of the study results.
STATA software (version 11.0; STATACorp, College Sta-
tion, TX, USA) was used to calculate the relative risks (RRs)
for the sensitivity and specificity of NBI vs the sensitivity and
specificity of WLB for the diagnosis of early or invasive lung
cancer. For these analyses, a p-value o0.05 was considered
significant. An RR41 indicated that NBI was more sensitive
than WLB for the detection of early invasive lung cancer.
Publication bias was analysed using a weighted linear regres-
sion model and a Deeks funnel plot (STATA software). An
asymmetric funnel plot was suggestive of possible publication
bias. The significance of the intercept was determined using
a t test, and a p-value o0.05 was indicative of statistically
significant publication bias. All p-values were two-sided, and
all confidence intervals (CIs) had a two-sided probability
coverage of 95%.
Figure 1 - Study flow diagram.
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’ RESULTS
Study identification and study quality
Of the 207 reports retrieved during the database search,
159 remained after the duplicate studies were eliminated,
and 28 remained after the titles and abstracts were screened.
Twenty-two studies were excluded after a full-text review for
the following reasons: (a) their biopsies were performed at
sites of abnormal fluorescence, (b) they reported insufficient
data with respect to their sensitivity and specificity calcula-
tions, (c) they were review articles, (d) their data were pre-
sented in more than one article, and (e) their full text was not
available (Figure 1).
Quality assessment
The results of the quality assessment of the eligible studies
are shown in Table 1. The studies included in the analysis
were generally of an ideal design.
NBI accuracy
Five prospective studies and one retrospective study
including a total of 578 patients were included in the anal-
ysis. The Spearman correlation coefficient for these studies
was 0.600, p=0.208, indicating that the lack of a definite
threshold effect produced heterogeneity. The I2 values for sen-
sitivity and specificity were 94.1% and 88.9%, respectively,
indicating that a high level of between-study heterogeneity
was present with respect these parameters because of the non-
threshold effect. When a random-effects model was used to
analyse the sensitivity and specificity of NBI for the detection
of early or invasive lung cancer, the pooled effect values
for the sensitivity, specificity, and AUC were 86% (95% CI: 83–
88%, I2=94.1%), 81% (95% CI: 77–84%, I2=88.9%), and 0.89
(Figure 2).
The efficacies of NBI and WLB
Four of the included articles (7-10) compared the diag-
nostic efficacies of NBI and WLB, and three of these articles
included data pertaining to patients with of moderate and
severe dysplasia. These four studies included a total of 381
patients and 1870 lesions. The pooled sensitivity and specificity
of NBI for the detection of early and invasive lung cancer were
91% (95% CI: 88–94%, I2=89%) and 81% (95% CI: 77–85%,
I2=93.1%), respectively, with an AUC of 0.92 (Figure 3). The
pooled sensitivity and specificity of WLB for the detection of
early and invasive lung cancer were 70% (95% CI: 66–74%,
I2=90.3%) and 66% (95% CI: 0.62–0.70, I2=72.8%), respec-
tively, with an AUC of 0.70 (Figure 4). The pooled RR for the
sensitivity of NBI vs the sensitivity of WLB for the detection
of early and invasive cancer was 1.33 (95% CI: 1.07–1.67),
and the corresponding pooled RR for the specificity of NBI
vs the specificity of WLB for the detection of early or invasive
Table 1 - Characteristics of the studies included in this meta-analysis
Study/year Nation No. of
subjects (n)
No. of
biopsies (n)
Average
age (yr)
M/F Control Statistical
index
Blind QUADAS
score
Gao et al./2014 (12) China 44 Unclear 58.3±13.8 34/10 No Per-patient Unclear 11
Li et al./2014 (9) China 196 1072 58±10 152/44 No Per-patient Yes 12
Chen et al./2014 (11) China 153 Unclear 57±11 106/47 No Per-patient Yes (partially blind) 12
Herth et al./2009 (7) Germany 57 98 Unclear Unclear No Per-patient Yes 11
Bojan et al./2009 (10) Serbia 106 636 55 85/21 Yes Per-lesion Yes 13
Vincent et al./2007 (8) America 22 64 59 8/14 Yes Per-lesion Yes (partially blind) 11
Table 1 - Characteristics of the studies included in this meta-analysis (continued)
Study/year Type of
investigation
NBI System No. of
endoscopists
Lesion
characterization
Study design Pathological
results
Gao et al./2014 (12) NBI EVIS LUCERA
(CV-260SL)
2 Shibuya’s
descriptors
Retrospective Cancer
Li et al./2014 (9) NBI, WLB EVIS LUCERA
(CV-260SL)
Unclear Shibuya’s
descriptors
Prospective Moderate to severe
dysplasia and Cancer
Chen et al./2014 (11) NBI, AFI+NBI, AFI EVIS LUCERA
(CV-260SL)
Unclear Shibuya’s
descriptors
Prospective Cancer
Herth et al./2009 (7) NBI, AFI, WLB and
combination
EVIS EXERA Unclear
(more than one)
Shibuya’s
descriptors
Prospective Moderate to severe dysplasia
and carcinoma in situ
Bojan et al./2009 (10) NBI, WLB EVIS LUCERA
(CV-260SL)
Unclear Shibuya’s
descriptors
Prospective Cancer
Vincent et al./2007 (8) NBI, WLB EVIS EXERA II 2 Shibuya’s
descriptors
Prospective Moderate to severe
dysplasia and cancer
Table 1 - Characteristics of studies included in this meta-analysis (continued)
Study/year No. of subjects (n) TP FP FN TN
Gao et al./2014 (12) 44 29 4 2 9
Li et al./2014 (9) 196 157 3 21 15
Chen et al./2014 (11) 153 87 4 50 12
Herth et al./2009 (7) 57 9 4 8 36
Bojan et al./2009 (10) 106 267 51 14 304
Vincent et al./2007 (8) 22 13 29 0 22
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cancer was 1.09 (95% CI: 0.84–1.42) (Figure 5). Thus, NBI
was significantly more sensitive than WLB with respect to
detecting early and invasive lung cancer; however, NBI and
WLB did not differ significantly with respect to specificity.
The value of NBI vs that of WLB for the diagnosis of
early lung cancer. We also searched for data regarding the
ability of NBI to accurately diagnose early lung cancer only
(7,8). The sensitivity and specificity of NBI for the diagnosis
of early lung cancer were 62% (95% CI: 38–82%, I2=77.3%)
and 58% (95% CI: 48–68%, I2=96.8%), respectively, whereas
the corresponding values for WLB were 14% (95% CI: 3–36%,
I2=27.6%) and 69% (95% CI: 59–78%, I2=91.4%), respectively.
The RR for the sensitivity of NBI vs the sensitivity of WLB for
Figure 2 - Six-study analysis of the ability of NBI to diagnose early lung cancer and invasive lung cancer. A. Pooled sensitivity of NBI for
the diagnosis of early lung cancer and invasive lung cancer; B. Pooled specificity of NBI for the diagnosis of early lung cancer and
invasive lung cancer; C. The summary receiver operating characteristic (SROC) curve for the diagnosis of early lung cancer and invasive
lung cancer by NBI.
Figure 3 - Four-study analysis of the ability of NBI to diagnose early lung cancer and invasive lung cancer. A. Pooled sensitivity of NBI for
the diagnosis of early lung cancer and invasive lung cancer; B. Pooled specificity of NBI for the diagnosis of early lung cancer and
invasive lung cancer; C. The SROC curve for the diagnosis of early lung cancer and invasive lung cancer by NBI.
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the diagnosis of early lung cancer was 3.86 (95% CI: 1.38–
10.75), and the RR for the specificity of NBI vs the specificity
of WLB for the diagnosis of early lung cancer was 0.83 (95%
CI: 0.45–1.53). Therefore, we concluded that NBI is superior
to WLB with respect to detecting early lung cancer. The
sensitivity and specificity of NBI were lower in the above
studies than in the cumulative results.
The value of NBI vs that of autofluorescence imaging
and NBI + autofluorescence imaging. In this study,
we also searched for data comparing the ability of NBI
to accurately diagnose early and invasive lung cancer with
that of autofluorescence imaging (AFI) and NBI+ AFI (7,11).
Only two studies including 210 patients were included in
this analysis, and we applied a fixed-effects model to pool
the effect sizes. The diagnostic sensitivity and specificity of
NBI for the diagnosis of early and invasive lung cancer were
62% (95% CI: 54–70%, I2=0.0%) and 86% (95% CI: 0.74–0.94,
I2=48.2%), respectively, whereas the corresponding val-
ues of AFI were 91% (95% CI: 85–95%, I2=90.7%) and
38% (95% CI: 25–51%, I2=0.0%), respectively. The RRs for
the sensitivity and specificity of NBI for the diagnosis of
early and invasive lung cancer were 0.69 (95% CI: 0.60–
0.78) and 2.29 (95% CI: 1.61–3.25), respectively.
The sensitivity and specificity of AFI + NBI for the
detection of early and invasive lung cancer were 93% (95% CI:
88–96%, I2=89.3%) and 54% (95% CI: 40–67%, I2=91.3%),
respectively, and the corresponding RRs were 0.67 (95% CI:
0.59–0.76) and 1.38 (95% CI: 0.49–3.90), respectively. There-
fore, we concluded that the sensitivity of NBI for the
diagnosis of early and invasive lung cancer was lower than
that of AFI + NBI; however the specificity of NBI for the
diagnosis of early and invasive lung cancer did not differ
significantly from that of AFI, suggesting that NBI and AFI
are complementary tests. Unfortunately, only two relevant
studies regarding the ability of these tests to diagnosis early
and invasive lung cancer were available; thus, additional
studies will be needed to confirm the abovementioned findings.
Sensitivity and meta-regression analysis
As shown in Table 2, we noted high heterogeneity in the
pooled effect sizes from the included studies. Therefore,
we performed sensitivity analysis of the ability of NBI to
diagnose early and invasive lung cancer using characteristics
from different types of studies, including prospective studies
and studies including X50 patients and using per-patient
statistics and different video endoscopy systems or patient
populations, as well as other studies (Table 2). In addition,
we sequentially excluded studies whose results deviated
significantly from the pooled effect size (7,8). The remaining
five and four studies were subjected to sensitivity analyses.
The AUCs of NBI for the diagnosis of early and invasive
cancer ranged from 0.83 to 0.93. These results indicated
that the diagnostic efficacy of NBI for early and invasive
cancer remained high and that the results of the study were
stable.
Several of the previously mentioned factors were also
selected for the meta-regression analysis (Table 3). Although
all the factors could be extracted from the six studies, the
sources of between-study heterogeneity were not identified.
Notably, the heterogeneity may have been caused by factors
that could not be assessed in the present analysis, namely,
patient age and sex ratios, because a portion of their data
were lost or were not reported.
Assessment of publication bias
In the publication bias analysis (STATA), the Deeks funnel
plot suggested that publication bias may have been present
among the included studies, and the corresponding p-value
of 0.02 indicated that statistically significant publication bias
was present among the included studies. As shown in the
Figure 4 - Four-study analysis of the ability of WLB to diagnose early lung cancer and invasive lung cancer. A. Pooled sensitivity of WLB
for the diagnosis of early lung cancer and invasive lung cancer; B. Pooled specificity of WLB for the diagnosis of early lung cancer and
invasive lung cancer; C. The SROC curve for the diagnosis of early lung cancer and invasive lung cancer by WLB.
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Deeks funnel plot (Figure 6), the angle of the regression line
and the diagnostic odds ratio axis diverged from 90o, sug-
gesting that publication bias was present among the inclu-
ded studies.
Complications
Two studies reported adverse effects. In one study, all the
adverse effects were attributed to bronchoscopy rather than
to the NBI devices. The other study reported slight bleeding
Figure 5 - A. The pooled RR for the sensitivity of NBI vs the sensitivity of WLB for the detection of early lung cancer and invasive lung
cancer; B. The pooled RR for the specificity of NBI vs the specificity of WLB for the detection of early lung cancer and invasive lung cancer.
Table 2 - Outcomes of the sensitivity analysis of selected studies assessing the stability of the accuracy of NBI for diagnosing early and
invasive lung cancer
Study characteristics No. of studies No. of patients Pooled estimatesd
Sensitivity Specificity
AUC
Inclusion populationa (8-12) 5 521 0.86 (0.84-0.89) 0.80 (0.76-0.84) 0.89
Prospective studies (8-11) 5 534 0.85 (0.82-0.88) 0.81 (0.77-0.84) 0.89
Studies with X50 patients (7,9-11) 4 512 0.85 (0.82-0.88) 0.86 (0.82-0.89) 0.91
EVIS LUCERA videoendoscopy system (9-12) 4 499 0.86 (0.83-0.89) 0.85 (0.81-0.88) 0.87
Final outcomeb (10-12) 3 303 0.86 (0.81-0.90) 0.67 (0.57-0.76) 0.89
Per-patient analysis (7, 9, 11, 12) 4 450 0.78 (0.73-0.82) 0.83 (0.73-0.90) 0.87
Blind (7-11) 5 534 0.85 (0.82-0.88) 0.81 (0.77-0.84) 0.89
No control (7,9,11,12) 4 450 0.78 (0.73-0.82) 0.83 (0.73-0.90) 0.87
Five studiesc (7,9-12) 5 556 0.85 (0.82-0.88) 0.85 (0.81-0.88) 0.90
Four studiesc (9-12) 4 499 0.86 (0.83-0.89) 0.85 (0.81-0.88) 0.87
a: Patients with known or suspected lung malignant lesions.
b: Pathological positive index was cancer.
c: Studies whose results deviated significantly from the pooled effect size were excluded, and sensitivity analyses of the remaining five and four studies
were performed.
d: The 95% confidence interval is given in parentheses.
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that was attributed to NBI but described no other NBI-
related complications.
’ DISCUSSION
Diagnosing lung cancer early is essential for effectively
treating the disease and optimizing survival. Bronchoscopy
is ideal for detecting lung cancer arising from the central
airway; however, detecting early and invasive lung cancer
and precancerous lesions using WLB remains difficult. Accord-
ing to a previous report, only 29% of CIS and 69% of
microinvasive cancer cases are identified by WLB, regardless
of the experience level of the bronchoscopist (16). The more
advanced AFI bronchoscopy exploits the autofluorescent
nature of the bronchial mucosa to detect tiny and subtle
superficial lesions. AFI has been shown to increase the yield
of diagnostic testing for early lung cancer (17-22); however,
its role in detecting lung neoplasia is limited by its specificity,
which is actually lower than that of WLB and leads to more
false positives (7,21,23,24).
NBI is an optical technique based on the use of narrower
blue and green light filters to enhance visualization of the
microvascular architecture and microsurface structures. This
technique, which offers chromoendoscopy without requiring
additional dye sprays, clearly highlights the micromorphol-
ogy and microvascular structures of mucosal lesions and
facilitates the identification of cancerous lesions (5,25-27).
NBI is simple and can be performed by general endoscopists;
however, it is also an accepted endoscopic diagnostic method
with defined standards for the diagnosis of early and
invasive lung cancer. The most widely used set of current
diagnostic standards was proposed by Shibuya, whose
‘‘descriptors’’ include dotted, tortuous, abruptly terminating
blood vessels (27).
NBI can distinguish cancer from benign lesions with a
high level of accuracy (6,25,26). Several articles have reported
the superiority of NBI over AFI and WLB because the former
detects cancerous lesions with higher specificity than the
latter; however its sensitivity is not significantly compro-
mised by its higher specificity (7-11,13,14). In a meta-analysis
of 14 studies (15 data sets), Chen et al. (23) compared the
ability of autofluorescence bronchoscopy (AFB) to detect
lung cancer and paraneoplastic lesions with that of WLB.
The pooled sensitivity and specificity for AFB were 90% (95%
CI: 84–93%) and 56% (95% CI: 45–66%), respectively, and the
pooled sensitivity and specificity for WLB were 66% (95% CI:
58–73%) and 69% (95% CI: 57–79%), respectively. Wang et al.
(21) also compared the ability of AFB to detect lung cancer
and precancerous lesions with that of WLB in a meta-
analysis of six studies. The pooled sensitivities of AFI and
WLB were 89% (95% CI: 81–94%) and 67% (95% CI: 46–83%),
respectively, and the pooled specificities of AFI and WLB
were 64% (95% CI: 37–84%) and 84% (95% CI: 74–91%),
respectively. Thus, AFI was more sensitive and less specific
than WLB for the detection for early and invasive lung
cancer. However, in the present meta-analysis, NBI had a
sensitivity of 86% (95% CI: 83–88%, I2=94.1%) and a
specificity 81% (95% CI: 77–84%, I2=88.9%) for the detection
of early and invasive lung cancer.
One systematic review (28) from 2001 that examined the
utility of positron emission tomography (PET) with respect
to the diagnosis of pulmonary nodules and mass lesions
included 40 studies that met its specific inclusion criteria.
PET was used to examine 1474 focal pulmonary lesions of
any size and was found to have a maximum joint sensitivity
and specificity (upper-left point on the receiver operating
characteristic curve at which sensitivity and specificity were
equal) of 91.2% (95% CI: 89.1–92.9%). The diagnostic
sensitivity and specificity of PET are superior to those of
NBI; however, PET is expensive, cannot be used to obtain
histological specimens, and exposes the patient to radiation.
The prognoses of patients with lung cancer depend heavily
on the stage at which patients are diagnosed with the
disease. According to the stepwise progression theory of
carcinogenesis, early detection of preinvasive lesions, such as
moderate or severe dysplasia or CIS, and subsequent prompt
surgical resection or endobronchial treatment will provide
the patient with the best chance of survival and lung function
conservation. Consistent with this idea, the reported 5-year
survival rate for patients treated for preinvasive (stage 0)
lung cancer exceeds 90% (29). However, in the current study,
only two articles (7,8) evaluated the ability of NBI and WLB
Table 3 - Meta-regression analysis of the potential sources of heterogeneity
Variables Coefficient Relative DOR (95% CI) p-value
Study design (prospective vs retrospective) 0.311 1.36 (0.01-285.42) 0.8650
Number of patients (X50 vs o50) 1.768 5.86 (0.05-750.93) 0.3303
Histology outcome (invasive cancer vs early lung cancer) -0.139 0.87 (0.02-33.32) 0.9111
Videoendoscopy system (Lucera vs EXERA) -0.604 0.55 (0.01-32.01) 0.6691
Statistical index (per-patient vs per-lesion) 1.400 4.06 (0.14-118.82) 0.2787
Included population (known or suspected lung malignancy vs high risk of lung malignancy) -0.083 0.92 (0.00-801.28) 0.9712
Figure 6 - Deeks funnel plot for the evaluation of publication
bias.
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to accurately diagnose early lung cancer. The sensitivity and
specificity of NBI for the diagnoses of early lung cancer were
62% and 58%, respectively, and the corresponding values
for WLB were 14% and 69%, respectively. The corresponding
RRs for the sensitivity and specificity were 3.86 (95% CI:
1.38–10.75) and 0.83 (95% CI: 0.45–1.53), respectively. Thus,
NBI appears to be superior to WLB with respect to detecting
early lung cancer. Unfortunately, only two relevant studies
regarding this issue were identified, and additional research
is needed to confirm the findings described herein.
NBI, a novel observational method, has facilitated patho-
logical diagnoses of lung cancer by allowing mass observa-
tion, guiding targeted biopsies, and enabling predictions of
pathological type (30); has improved assessments of exten-
sion; and has influenced therapeutic strategies (9,10,14).
The results of our meta-analysis suggest that NBI is highly
accurate with respect to diagnosing lung neoplasms.
An article (7) included in the analysis had accepted
patients who were at high risk for lung cancer (i.e., patients
without a known diagnosis or clinical findings suggestive
of central airway malignancies). In that study, a histologic
tumour grade of moderate to severe dysplasia or CIS (via
biopsy) was considered a positive diagnosis of intraepithelial
neoplasia. However, that study reported a lower NBI sen-
sitivity for the detection of lung cancer than other recent
articles (13,18). This discrepancy can be explained by the
ability of endoscopy to distinguish between ‘‘abnormal’’ and
‘‘suspicious’’ lesions and the researchers’ subsequent deci-
sion to consider only suspicious lesions to be positive diag-
nostic findings on bronchoscopy. Not all previous studies
made this distinction, and if that study had considered both
abnormal and suspicious lesions to be ‘‘positive broncho-
scopic findings’’, NBI would have identified 100% of the
high-grade dysplastic lesions and CIS affecting the patients
enrolled therein. Similarly, Vincent et al. (8) reported that NBI
identified dysplasias or malignancies that were not detected
by WLB in 23% of patients. However, NBI did not detect
these lesions with greater accuracy in areas with abnormal
WLB findings. Further studies are needed to determine the
efficacy of NBI with respect to the detection of premalignant
airway lesions in at-risk populations.
In an earlier article, Herth reported that AFI, NBI, and
NBI+ AFI exhibited sensitivities of 65%, 53%, and 71% and
specificities of 40%, 90%, and 40%, respectively, for the diag-
nosis of early lung cancer (7). Although NBI was signifi-
cantly more specific than AFI with respect to diagnosing
cancer (po0.001), these modalities did not differ significantly
with regards to sensitivity (p=0.49). Furthermore, although
the relative sensitivity for the combination of AFI and NBI vs
WLB was 4.0, the combined test did not exhibit improved
specificity compared with either AFI alone or NBI alone
(p=0.56). The specificity of AFI + NBI was equal to that of
AFI and significantly lower than that of NBI; thus, this
combination led to a nonsignificant increase in lung cancer
diagnostic yield. In summary, this study demonstrated that
NBI can be used alone as a first-choice lung cancer diagnostic
modality rather than in combination with other diagnostic
modalities.
According to Chen (11), the diagnostic sensitivities of NBI,
AFI, and NBI + AFI for the detection of central lung cancer
were 63.5%, 94.2%, and 95.6%, respectively, and the speci-
ficities of these tests for the detection of central lung cancer
were 75.0%, 31.3%, and 87.5%, respectively. The specificity
and sensitivity of NBI were significantly higher and lower
than those of AFI, respectively, suggesting that NBI and AFI
are complementary tests. In that study, NBI+ AFB and AFB
alone differed significantly with respect to their specificities
(po0.01) but not their sensitivities (p40.05) for the diagnosis
of early and invasive lung cancer, whereas NBI + AFB and
NBI alone differed significantly with regards to both their
sensitivities and their specificities for the diagnosis of early
and invasive lung cancer (po0.01 and p=0.03, respectively).
Chen concluded that NBI+ AFB could diagnose lung cancer
with greater specificity than AFB alone, a notable finding
that contradicted those reported by Herth. This discrepancy
may be attributable to the following factors: 1. The study by
Chen addressed obvious bronchial and pulmonary masses
and used the above diagnostic techniques only to observe
mucosal abnormalities. Moreover, the patients eligible for
inclusion in the study were not at high risk for lung cancer.
Therefore, that study differed from the study performed by
Herth, as it lacked data regarding certain study parameters,
as well as data regarding precancerous lesions. 2. The posi-
tive diagnosis rate reported by Chen pertained to patients
rather than lesions. The discrepancies between these two
studies have necessitated additional high quality research to
determine whether NBI+ AFB is superior to either modality
alone with respect to diagnosing cancer.
Despite these differences, the study by Chen demonstrated
the distinct advantages of the above modalities. AFB is used
to observe surface mucosal changes, and NBI is used to
observe surface mucosal vascular lesions. When used in
combination, each modality can compensate for the short-
comings of the other. However, AFI and NBI are not
currently integrated into single bronchoscope units. In the
future, the combined use of these technologies may reduce
inspection times and patient discomfort. In our meta-
analysis, which included 578 patients, only one article
reported slight bleeding. Therefore, we believe that NBI,
which has high diagnostic value and a low complication
rate, may be an accurate, safe, and cost-effective tool for
diagnosing early lung and invasive lung cancer.
Limitations
Our analysis had some limitations. First, we included only
six studies in the analysis. Second, we were unable to
identify the sources of heterogeneity among the studies
included herein. Although one could argue that heterogene-
ity is inevitable in a meta-analysis regardless of whether its
presence is detectable via statistical analysis, its existence
limits the clinical application of the results of the analysis.
The heterogeneity noted herein may be attributed to
differences in the time spans of the included studies, the
use of different types of bronchoscopes, differences in the
experience levels of the endoscopists and pathologists who
performed the bronchoscopies and biopsies, diagnostic
research on small sample sizes, differences in sex ratios and
age distributions, and differences in pathological results.
Furthermore, in some of the studies included in the analysis,
tissue samples biopsied from visually normal areas, as
demonstrated by both NBI and WLB, were used as controls;
however, other studies included in the analysis did not
perform control biopsies. Third, in our subgroup analysis, we
compared the diagnostic accuracies of NBI, AFI and AFI +
NBI; however, we identified only two studies that perfor-
med these comparisons. Therefore, our conclusions regard-
ing the relative efficacies of those modalities require further
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verification in future studies. Fourth, all the included studies
used an earlier bronchoscope model. The newest NBI
bronchoscope is the OLYMPUS BF-H290, which produces
clearer images than earlier models but is expensive. To date,
no published studies have used this bronchoscope. Finally,
publication bias was inevitable because we did not search for
unpublished data, and data regarding TP, FP, TN, and FN
diagnoses could not be extracted from the sensitivity and
specificity calculations of two relevant studies (13,14). In
addition, we included only English- and Chinese-language
studies from four major databases and therefore may have
overlooked some important articles published in other
countries and languages. Furthermore, the reports included
herein seldom described whether their patients were con-
secutively or randomly selected, an omission that may also
have been a source of bias.
NBI is an accurate, safe, and cost-effective tool for diag-
nosing lung cancer. The current evidence indicates that NBI
is more valuable than WLB with respect to diagnosing both
early and invasive lung cancer and that it is both feasible
and convenient to switch between these two modalities as
technologies advance. Our findings indicate that NBI is
superior to WLB and that its use may lead to improvements
in diagnostic yields, as well as improvements in sensitivity
for the diagnosis of cancer that do not compromise speci-
ficity. However, additional high-quality prospective studies
regarding the ability of NBI to diagnose early and invasive
lung cancer remain necessary.
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